High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients

Blood

Volumn 113, Issue 8, 2009, Pages 1749-1755

  Tyner, Jeffrey W ^a   Erickson, Heidi ^a   Deininger, Michael W N ^a   Willis, Stephanie G ^a   Eide, Christopher A ^a   Levine, Ross L ^b,c   Heinrich, Michael C ^a,d   Gattermann, Norbert ^e   Gilliland, D Gary ^b,c   Druker, Brian J ^a,b   Loriaux, Marc M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

^e UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RAS PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLELE; ANIMAL CELL; ARTICLE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; EMBRYO; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HYPOTHESIS; INFANT; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MOUSE; MYELOID LEUKEMIA; NONHUMAN; ONCOGENE K RAS; ONCOGENE N RAS; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION;

EID: 61849150985     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-04-152157     Document Type: Article

References (33)

1. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-4689.
2. Bartram CR. Mutations in ras genes in myelocytic leukemias and myelodysplastic syndromes. Blood Cells. 1988;14:533-538.
3. Janssen JW, Lyons J, Steenvoorden AC, Seliger H, Bartram CR. Concurrent mutations in two different ras genes in acute myelocytic leukemias. Nucleic Acids Res. 1987;15:5669-5680.
4. Janssen JW, Steenvoorden AC, Lyons J, et al. RAS gene mutations in acute and chronic myelo-cytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. Proc Natl Acad Sci U S A. 1987;84:9228-9232.
5. NeubauerA, Dodge RK, George SL, et al. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood. 1994;83:1603-1611.
6. Shen WP, Aldrich TH, Venta-Perez G, Franza BR Jr, Furth ME. Expression of normal and mutant ras proteins in human acute leukemia. Onco-gene. 1987;1:157-165.
7. Edkins S, O'Meara S, Parker A, et al. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther. 2006;5:928-932.
8. Sjöblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314: 268-274.
9. Birnbaum RA, O'MarcaighA, Wardak Z, et al. Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol Cell. 2000;5:189-195.
10. Lauchle JO, Braun BS, Loh ML, Shannon K. Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatr Blood Cancer. 2006;46:579-585.
11. Le DT, Kong N, Zhu Y, et al. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood. 2004;103: 4243-4250.
12. Loh ML, Vattikuti S, Schubbert S, et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood. 2004;103:2325-2331.
13. Miles DK, Freedman MH, Stephens K, et al. Patterns of hematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant myeloid disorders. Blood. 1996;88:4314-4320.
14. Schubbert S, Lieuw K, Rowe SL, et al. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood. 2005; 106:311-317.
15. Side LE, Emanuel PD, Taylor B, et al. Mutations of the NF1 gene in children with juvenile myelomono-cytic leukemia without clinical evidence of neurofibro-matosis, type 1. Blood. 1998;92:267-272.
16. Niihori T, Aoki Y, Narumi Y, et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet. 2006;38:294-296.
17. Schubbert S, Bollag G, Lyubynska N, et al. Biochemical and functional characterization of germ line KRAS mutations. Mol Cell Biol. 2007;27: 7765-7770.
18. Schubbert S, Zenker M, Rowe SL, et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet. 2006;38:331-336.
19. Loriaux MM, Levine RL, Tyner JW, et al. High-throughput sequence analysis of the tyrosine ki-nome in acute myeloid leukemia. Blood. 2008; 111:4788-4796.
20. Bowen DT, Frew ME, Hills R, et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood. 2005;106:2113-2119.
21. Gardner AM, Vaillancourt RR, Johnson GL. Activation of mitogen-activated protein kinase/extra-cellular signal-regulated kinase kinase by G protein and tyrosine kinase oncoproteins. J Biol Chem. 1993;268:17896-17901.
22. Kolch W, Heidecker G, Lloyd P, Rapp UR. Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature. 1991;349:426-428.
23. Macdonald SG, Crews CM, Wu L, et al. Reconstitu-tion of the Raf-1-MEK-ERK signal transduction pathway in vitro. Mol Cell Biol. 1993;13:6615-6620.
24. Thomas SM, DeMarco M, D'Arcangelo G, Halegoua S, Brugge JS. Ras is essential for nerve growth factor- and phorbol ester-induced tyrosine phosphorylation of MAP kinases. Cell. 1992;68:1031-1040.
25. Wood KW, Sarnecki C, Roberts TM, Blenis J. ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK. Cell. 1992;68: 1041-1050.
26. Stouten PF, Sander C, Wittinghofer A, Valencia A. How does the switch II region of G-domains work? FEBS Lett. 1993;320:1-6.
27. Orita S, Higashi T, Kawasaki Y, et al. A novel point mutation at codon 146 of the K-ras gene in a human colorectal cancer identified by the polymerase chain reaction. Virus Genes. 1991; 5:75-79.
28. Feig LA, Cooper GM. Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins. Mol Cell Biol. 1988;8:2472-2478.
29. Sloan SR, Newcomb EW, PellicerA. Neutron radiation can activate K-ras via a point mutation in codon 146 and induces a different spectrum of ras mutations than does gamma radiation. Mol Cell Biol. 1990;10:405-408.
30. Blum R, Cox AD, Kloog Y. Inhibitors of chronically active ras: potential for treatment of human malignancies. Recent Patents Anticancer Drug Discov. 2008;3:31-37.
31. Blum R, Kloog Y. Tailoring Ras-pathway-inhibitor combinations for cancer therapy. Drug Resist Up-dat. 2005;8:369-380.
32. Rodriguez-Viciana P, Tetsu O, Oda K, Okada J, Rauen K, McCormick F. Cancer targets in the Ras pathway. Cold Spring Harb Symp Quant Biol. 2005;70:461-467.
33. Smith RA, Dumas J,Adnane L, Wilhelm SM. Recent advances in the research and development of RAF kinase inhibitors. Curr Top Med Chem. 2006;6:1071-1089.